Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
Table of Contents What Is Retatrutide and Its Current Development Status in the UK Risks of Sourcing Unregulated Peptides Online MHRA Guidance on Unlicensed Weight Loss Treatments Approved Alternatives Available Through NHS and Private Clinics How to Speak to a UK Doctor About Emerging Weight Loss Options Scientific References Frequently Asked Questions What Is Retatrutide and Its Current Development Status in the UK Retatrutide is an investigational triple incretin receptor agonist (GLP-1, GIP, and glucagon) developed by Eli Lilly that remains in Phase 3 trials and holds no MHRA marketing authorisation as of mid-2025
If you're thinking about starting these medications, it's a good idea to talk to your healthcare provider or pharmacist about costs and any available financial assistance programs
Semaglutide GLP-1 enhances insulin release, particularly when blood sugar levels are elevated, thereby aiding in better glucose control
When disclosing, provide the specifics
Both GLP-1 injections and oral GLP-1 medications mimic the effects of a naturally occurring peptide called Glucagon-like peptide 1
